UCB presents new data on Vimpat and health care costs associated with epilepsy at IEC meeting

Consistent evidence that adjunctive treatment with epilepsy drug Vimpat (lacosamide) was generally well tolerated and associated with a sustained reduction in partial onset seizures for up to eight years, was presented this week at the 29th International Epilepsy Congress taking place in Rome, Italy, by Belgium’s largest drugmaker UCB ( UCB: BR).

“These data showed that the seizure control and tolerability seen with lacosamide in pivotal Phase III clinical trials were maintained during open label long term studies, and they provide additional clinical data to neurologists searching for long term solutions for adult patients with poorly controlled partial onset seizures,” said Robert Leroy, Neurological Clinic of Texas, Dallas, USA.

A further study announced at the Congress - VITOBA (VIpatT added to One Baseline AED) - is investigating whether lacosamide has additive or synergistic effects when added to single agent AED treatment for partial onset seizures in a real life clinical setting. Analysis of data from this six month, prospective, non-interventional study of 500 evaluable patients with partial onset seizures should provide comparative insights into the effects of adding lacosamide to a single “sodium channel” or “non-sodium channel” AED.